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Abstract
The proliferation of new technology platforms and tools is dramatically advancing our ability to capture, integrate and
use clinical and other health related data for research and care. Another critical and increasingly common source of data
comes directly from patients – often in the form of Patient Reported Outcomes (PRO). As more providers and payers
recognize that patient experiences reflect a critical dimension of the value proposition, these data are informing broader
strategies to achieve performance improvement and accountability in health systems. Combined with other traditional
(e.g., claims) and more recent (e.g., Electronic Health Record) data assets, PROs can help to examine experiences and
outcomes that convey a more complete picture of both individual and population health. One of the areas of research
where this is most evident is cancer survivorship, including long-term adverse effects, as the population of survivors is
increasing given advances in detection and treatment.
Key questions remain as to how and under what conditions these new data resources can be used for research, and
which are the best “sources of truth” for specific types of information. A recent IJHPR validation study by Hamood et al.
reflects important progress in this regard, and establishes the necessary groundwork for a larger planned study. There
are some important limitations worth noting, such as a small sample size (which does not support adequate subgroup
analysis); a relatively narrow focus on women with only early stage or regionally advanced breast cancer; and a limited
focus on outcomes that are primarily clinical and relatively severe in nature (e.g., cardiovascular disease).
Finally, as use of EHRs becomes ubiquitous, as patient perspectives and outcome measures are considered, and as more
types of data are systematically collected via electronic systems, further comparison and validation of non-clinical data
elements captured via such tools will become increasingly possible and important. This will further enhance the capacity
of cancer survivorship researchers to address a broader range of important questions to many more types of patients.
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Background
The proliferation of new technology platforms and tools
is dramatically advancing our ability to capture, integrate
and use clinical and other health related data for re-
search and care. In the United States (US), the pace of
technological innovation was accelerated by the policies
and financial incentives offered to stimulate the adoption
of electronic health records (EHR) established by the
HITECH Act of 2009; it was further advanced by a num-
ber of provisions in the Affordable Care Act that lever-
age data systems to transition payments from volume to
value.
Another critical source of data comes directly from pa-
tients – often in the form of Patient Reported Outcomes
(PRO). These PRO data are of increasing interest, as
more providers and payers recognize that patient experi-
ences reflect a critical dimension of the value propos-
ition. This is happening both in the US and globally, as
part of broader strategies to achieve performance
improvement and accountability in health systems [1–3].
Combined with other traditional (e.g., claims) and more
recent (e.g., EHR) data assets, PROs can help to examine
experiences and outcomes that convey a more complete
picture of both individual and population health. One of
the areas of research where this is most evident is cancer
survivorship, including long-term adverse effects, as the
population of survivors is increasing given advances in
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detection and treatment [4, 5]. A recent systematic
evaluation of nearly 800 adverse events listed in the
Common Terminology Criteria for Adverse Events
(CTCAE) identified 78 appropriate for patient self-
reporting [6]. Together, these policy shifts and technol-
ogy trends are enabling unprecedented integrations of
multiple data sources and systems to advance learning
health systems for all patients, including those treated
for cancer [7–9]. Key questions remain, however, as to
how and under what conditions these new data re-
sources can be used, and which are the best “sources of
truth” for specific types of information.
Discussion
We applaud the efforts of Hamood et. al. [10] to explore
the validity of different data sources for use in cancer
survivorship research; such assessments of data quality,
completeness and comparability are critically important
- both to understanding and characterizing existing data
assets, and to further building a robust research data in-
frastructure. While that feasibility study, which was re-
cently published in the Israel Journal of Health Policy
Research, reflects important progress in this regard,
some limitations are worth noting. For example, the
study’s focus on women with only early stage or region-
ally advanced breast cancer limits the generalizability of
findings, as women with more advanced disease may be
particularly at risk of adverse events and poor outcomes
and may be more or less willing to participate in PRO
measurement. A related point is that, as a feasibility
study, the sample size does not support sub-group ana-
lyses that would help identify patients less likely to
participate in PRO studies or with different care experi-
ences that could differ by age, cancer stage, or estrogen
sensitivity. It may be that the data quality and complete-
ness are similar for all regardless of such differences, but
the lack of assessment in this work leaves unanswered
questions – particularly for researchers wishing to con-
duct studies relevant to older and/or sicker patient pop-
ulations using these data tools.
Also worth noting is that - to the extent that a primary
aim of this study is to assess the comparability of admin-
istrative claims data relative to EHR data - the authors
have a priori limited the outcomes of interest to those
that are clinical and relatively severe in nature (e.g.,
cardiovascular disease). In this study, other important
sequela (e.g., impact on relationships, employment) ex-
perienced by cancer survivors are captured via the self-
reported questionnaire but, as indicated by the authors,
such tools can only accommodate a small number of
these questions without significantly increasing response
burden. In neither case is it clear the extent to which
patients and their caregivers were involved or consulted
in the process of determining primary outcomes for
assessment, but this is increasingly of interest – if not
yet standard practice. Over time, as use of EHRs be-
comes ubiquitous, as patient perspectives and outcome
measures are considered, and as more types of data are
systematically collected via EHR systems, further com-
parison and validation of non-clinical data elements cap-
tured via such tools will become increasingly possible
and important [11]. This will further enhance the cap-
acity of cancer survivorship researchers to address a
broader range of important questions to many more
types of patients.
Finally, and perhaps most importantly, we wonder about
the extent to which the methods applied and conclusions
drawn from this effort will hold true when it is deployed
across multiple institutions and with a far more diverse
patient population. This is certainly an area of tremendous
interest, and warrants further consideration.
Conclusion
Leveraging multiple sources and types of data to assess
and improve the quality and outcomes of care is now a
fundamental strategy for any learning health system. As
many of these sources are relatively new and rapidly
evolving, efforts to understand underlying quality, reli-
ability and feasibility of each data source is critical, as
this small study demonstrates. Also worth noting is that
this process of data source assessment and validation is
likely to require continuous monitoring and updating;
over time, and as health care providers are able to col-
lect more and better quality data via EHRs (and more
easily via natural language processing), the characteris-
tics and applicability of data in these systems will evolve.
The same holds true for data captured via personal de-
vices and other novel sources that will enable re-
searchers to more deeply explore the contexts and
outcomes critical to patient health and wellbeing.
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